News

Article

AJMC® in the Press, August 2, 2024

Author(s):

AJMC Staff

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

An article from Managed Healthcare Executive® referenced an article published on AJMC.com, the website of The American Journal of Managed Care® (AJMC®). The article, “Deuruxolitinib Demonstrates Efficacy, Tolerability in Patients With Moderate to Severe AA,” highlighted results from a poster presented at the 2024 American Academy of Dermatology Annual Meeting, which found that the Janus kinase inhibitor deuruxolitinib resulted in hair regrowth in patients with moderate to severe alopecia areata, with efficacy and tolerability.

An article from Pharmacy Times® referenced a resource published by AJMC’s sister site, The Center for Biosimilars®. The page, “The Center for Biosimilars: Biosimilars Approvals,” lists all 49 approved biosimilars in the US, including the name of each drug and the conditions it treats.

Related Videos
Anna-Maria Hoffmann-Vold, MD, PhD, a senior consultant and leader of inflammatory and fibrotic research area at Oslo University Hospital
Io Hui, PhD, researcher at The University of Edinburgh
Klaus Rabe, MD, PhD, chest physician and professor of medicine, University of Kiel
Adam Colborn, JD, of AMCP
Corey McEwen, PharmD, MS
Daniel Howell, MBBS
Related Content
FDA approve graphic on screen over a doctor | Image credit: wladimir1804 - stock.adobe.com
October 11th 2024

FDA Approves Imuldosa, a Fifth Biosimilar to Stelara

Skylar Jeremias
Imuldosa (ustekinumab-srlf) is the fifth ustekinumab biosimilar referencing Stelara to receive regulatory approval in the US.
managed care cast logo
October 3rd 2024

Dr Rick Chapman Discusses Key Insights From the Center’s Rare Disease Project

Brooke McCormick
On this episode of Managed Care Cast, we're talking with the chief science officer of the Center for Innovation & Value Research about key insights from its Rare Disease project.
Red blood cells | Image credit: Getty Images
October 11th 2024

FDA Approves Marstacimab, First Weekly Sub-Q Option for Hemophilia B

Mary Caffrey
Sustaining Compassionate Trauma Care Across Communities
September 30th 2024

Sustaining Compassionate Trauma Care Across Communities

Maggie L. Shaw
September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In our final episode, we speak with Lyndra Bills, MD, and Shari Hutchison, MS.
FDA Approved
October 11th 2024

FDA Approves Inavolisib in Locally Advanced, Metastatic Breast Cancer

Julia Bonavitacola
Patients with endocrine-resistant, HER2-negative, locally advanced or metastatic breast cancer can use the treatment after recurrence or completing adjuvant endocrine therapy.
Cancer cells | Image credit: Sodapeaw - stock.adobe.com
October 11th 2024

In Lower-Risk MDS, Genomic Dynamics Heighten Likelihood of Treatment

Jared Kaltwasser
The study is among the first to look at the potential impacts of clonal dynamics on patients with lower-risk myelodysplastic syndromes (MDS).

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo